New chairman of the SIOPEL group

Dear Colleagues,

We would like to inform all of you that a new chairman of the SIOPEL group has been elected who is dr. Bruce Morland, pediatric oncologist from Birmingham, UK.


See details above		 Hepatoblastoma GWAS study

Dear Colleagues,

Please read an enclosed letter of professor Logan Spector and if you are interested in participating in his hepatoblastoma GWAS study, reply directly to him.

Sincerely

Prof. Piotr Czauderna,

Past SIOPEL Chair


Hepatoblastoma GWAS

Childhood Liver Tumours Strategy Group - SIOPEL

The ultimate goal of the SIOPEL study group is to improve the prognosis and the quality of life of children affected by primary childhood liver tumors.

Primary hepatic tumours represent less than 1% of all childhood malignancies. Their frequency according to the different series is of about 0.8 - 1 case per million children less than 15 years of age per year. Hepatoblastoma (HB) is by far the commonest histological subtype of primary malignant hepatic tumours occurring in children less than 15 years of age, followed by hepatocellular carcinoma (HCC).

SIOPEL Group is composed of basic and clinical scientists coming from different European and Extra-European countries.